In this session Felix Gold Executive Director Joseph Webb discussed Auger sampling results from the NE Fairbanks Project confirming significant soil anomalies, with peak gold values of 568 ppb Au.

In this session Propell CEO Michael Davidson discussed Propell’s Q1 Financial results, which include the company’s first quarterly cash profit since listing in April 2021.

In this session Non-Executive Director Joe Ariti delves into Genmin’s Baniaka project, highlighting its high-grade greener iron ore deposit and promising economics, driven by projected low operating costs and minimal capital expenditure requirements.

In this session Felix Gold Executive Director Joseph Webb discussed how their strongly supported $4.8m placement positions Felix for its near-term antimony production aspiration, aiming for 5,000 tons a year from late 2025.

In this session Felix Gold Executive Director Joseph Webb discussed the significance of Felix’s exceptional high-grade antimony assay results and the potential of near-term low capex production, including collaboration with relevant U.S. government agencies.

In this session Far East Gold’s Non-Executive Chairman Justin Werner details of the strategic investment by Xingye, targeting over A$14 million for a 19.99% stake.

In this session Far East Gold’s newly appointed Non-Executive Chairman Justin Werner discussed what the potentially transformative Idenburg acquisition could mean for Far East Gold.

In this session Far East Gold’s CEO and Director Shane Menere and newly appointed Non-Executive Chairman Justin Werner discussed what the potentially transformative Idenburg acquisition could mean for Far East Gold.

In this session Felix Gold Executive Director Joseph Webb discussed their plans to grow and develop NW Array’s 467koz resource.

In this session Far East Gold’s CEO and Director Shane Menere discussed the standout assays from our Woyla drilling campaigns that form the base of our upcoming maiden JORC resource publication.

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed why the data from their PTX-100 Phase 1b trial is so promising.

Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.